| Symbol | TEVA |
|---|---|
| Name | TEVA PHARMACEUTICAL INDUSTRIES LTD. |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | - |
| Address | 49131 Israel 5 Basel Street, P.O. Box 3190 |
| Telephone | 972-3-914-8213 |
| Fax | 03-9267519 |
| yael.ashman@teva.co.il | |
| Website | http://www.tevapharm.com |
| Incorporation | IL |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;TASE;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0000818686 |
| Description | Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines. Additional info from NASDAQ: |
2026-09-10 10:04
Teva Pharmaceutical Industries Ltd. - Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Read more
2026-09-07 07:54
Teva Pharmaceutical Industries Ltd. -Teva Announces Launch of Offering of Senior Notes
Read more
2026-09-04 15:31
Teva Pharmaceutical Industries Ltd. - S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05532358 | A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Poten… | Phase1 | Healthy Volunteers | Completed | 2022-09-12 | 2023-02-10 | ClinicalTrials.gov |
| NCT04358068 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospi… | Phase2 | COVID-19 | Terminated | 2020-05-13 | 2020-07-08 | ClinicalTrials.gov |
| NCT03949673 | Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | Phase2 | Osteoarthritis, Knee | Terminated | 2019-04-08 | 2020-08-25 | ClinicalTrials.gov |
| NCT03491904 | To Assess the Patients' Ability to Self-Administer Fasinumab | Phase1 | Osteoarthritis, Knee | Completed | 2019-01-23 | 2020-12-15 | ClinicalTrials.gov |
| NCT03691974 | Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Pati… | Phase2 | Osteoarthritis, Knee | Completed | 2018-10-15 | 2021-01-07 | ClinicalTrials.gov |
| NCT03285646 | Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Seve… | Phase3 | Chronic Low Back Pain | Terminated | 2017-10-30 | 2019-05-02 | ClinicalTrials.gov |
| NCT03304379 | Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo… | Phase3 | Osteoarthritis, Knee | Completed | 2017-10-26 | 2020-11-09 | ClinicalTrials.gov |
| NCT03161093 | A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Place… | Phase3 | Osteoarthritis, Knee | Completed | 2017-08-17 | 2021-08-27 | ClinicalTrials.gov |
| NCT02835794 | A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Fac… | Phase1 | Myelodysplastic Syndromes | Withdrawn | 2016-08-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02683239 | Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to O… | Phase3 | Osteoarthritis of the Knee or Hip | Completed | 2016-02-17 | 2021-06-15 | ClinicalTrials.gov |
| NCT02515643 | Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Dono… | — | Disorder Related to Renal Transplantation | Unknown | 2015-07-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02907723 | Feasibility of Continuous Sleep Recording in Patients Undergoing Deep Brain Sti… | Na | Parkinson Disease | Completed | 2014-12-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patient… | Phase2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Terminated | 2014-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02092077 | A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Grow… | Phase2 | Growth Hormone-Deficiency | Terminated | 2014-04-30 | 2016-08-31 | ClinicalTrials.gov |
| NCT02552303 | The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armoda… | Na | Sleep Apnea | Completed | 2014-04-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01123070 | TL011 in Severe, Active Rheumatoid Arthritis Patients | Phase1 | Rheumatoid Arthritis | Completed | 2010-02-05 | 2012-04-23 | ClinicalTrials.gov |
| NCT00326625 | Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2006-07-27 | 2008-06-17 | ClinicalTrials.gov |
| NCT00745615 | An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and… | Phase2 | Relapsing Remitting Multiple Sclerosis | Terminated | 2005-12-07 | 2017-07-23 | ClinicalTrials.gov |
Total clinical trials: 18
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Approved | Sleep Apnea | COMPLETED | NCT02552303 |
| Armodafinil | Other | Approved | Sleep Apnea | COMPLETED | NCT02552303 |
| Cognitive Behavioral Therapy for Insomnia | Drug | Approved | Sleep Apnea | COMPLETED | NCT02552303 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Celecoxib | Other | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Diclofenac | Other | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Naproxen | Other | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Fasinumab | Other | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| decitabine | Other | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| omacetaxine mepesuccinate | Other | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| Endothelial dysfunction | Other | Preclinical | Disorder Related to Renal Transplantation | UNKNOWN | NCT02515643 |
| G-CSF | Other | Phase PHASE1 | Myelodysplastic Syndromes | WITHDRAWN | NCT02835794 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndromes | WITHDRAWN | NCT02835794 |
| Omacetaxine | Other | Phase PHASE1 | Myelodysplastic Syndromes | WITHDRAWN | NCT02835794 |
| Sleep Recording | Other | Approved | Parkinson Disease | COMPLETED | NCT02907723 |
| Fasinumab PFS | Other | Phase PHASE1 | Osteoarthritis, Knee | COMPLETED | NCT03491904 |
| Fasinumab AI | Other | Phase PHASE1 | Osteoarthritis, Knee | COMPLETED | NCT03491904 |
| Placebo | Other | Phase PHASE3 | Chronic Low Back Pain | TERMINATED | NCT03285646 |
| Fasinumab | Other | Phase PHASE3 | Chronic Low Back Pain | TERMINATED | NCT03285646 |
| MabThera infusions | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01123070 |
| TL011, anti CD20, for the treatment of rheumatoid arthritis | Drug | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01123070 |
| somatropin | Other | Phase PHASE2 | Growth Hormone-Deficiency | TERMINATED | NCT02092077 |
| TV-1106 | Other | Phase PHASE2 | Growth Hormone-Deficiency | TERMINATED | NCT02092077 |
| Placebo for Azithromycin | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Placebo for Hydroxychloroquine | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Azithromycin (Azithro) | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Hydroxychloroquine (HCQ) | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Naproxen-matching placebo | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03161093 |
| Fasinumab-matching placebo | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03161093 |
| Naproxen | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03161093 |
| Fasinumab | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03161093 |
| Matching placebo | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03304379 |
| Celecoxib | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03304379 |
| Diclofenac | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03304379 |
| Fasinumab | Other | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03304379 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT03691974 |
| Fasinumab | Other | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT03691974 |
| Fluvoxamine 100 mg QD for 5 days | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05532358 |
| anle138b (TEV-56286) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05532358 |
| Placebo | Other | Phase PHASE3 | Osteoarthritis of the Knee or Hip | COMPLETED | NCT02683239 |
| Fasinumab | Other | Phase PHASE3 | Osteoarthritis of the Knee or Hip | COMPLETED | NCT02683239 |
| Fluvoxamine 100 mg QD for 5 days | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05532358 |
| anle138b (TEV-56286) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05532358 |
| Placebo for Azithromycin | DRUG | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Placebo for Hydroxychloroquine | DRUG | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Azithromycin (Azithro) | DRUG | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Hydroxychloroquine (HCQ) | DRUG | Phase PHASE2 | COVID-19 | TERMINATED | NCT04358068 |
| Fasinumab PFS | DRUG | Phase PHASE1 | Osteoarthritis, Knee | COMPLETED | NCT03491904 |
| Fasinumab AI | DRUG | Phase PHASE1 | Osteoarthritis, Knee | COMPLETED | NCT03491904 |
| Matching placebo | DRUG | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03304379 |
| Celecoxib | DRUG | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Diclofenac | DRUG | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Naproxen-matching placebo | DRUG | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03161093 |
| Fasinumab-matching placebo | DRUG | Phase PHASE3 | Osteoarthritis, Knee | COMPLETED | NCT03161093 |
| Naproxen | DRUG | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Sleep Recording | DEVICE | Approved | Parkinson Disease | COMPLETED | NCT02907723 |
| G-CSF | DRUG | Phase PHASE1 | Myelodysplastic Syndromes | WITHDRAWN | NCT02835794 |
| Azacitidine | DRUG | Phase PHASE1 | Myelodysplastic Syndromes | WITHDRAWN | NCT02835794 |
| Omacetaxine | DRUG | Phase PHASE1 | Myelodysplastic Syndromes | WITHDRAWN | NCT02835794 |
| Fasinumab | DRUG | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| Armodafinil | DRUG | Approved | Sleep Apnea | COMPLETED | NCT02552303 |
| Cognitive Behavioral Therapy for Insomnia | BEHAVIORAL | Approved | Sleep Apnea | COMPLETED | NCT02552303 |
| Endothelial dysfunction | OTHER | Preclinical | Disorder Related to Renal Transplantation | UNKNOWN | NCT02515643 |
| somatropin | DRUG | Phase PHASE2 | Growth Hormone-Deficiency | TERMINATED | NCT02092077 |
| TV-1106 | DRUG | Phase PHASE2 | Growth Hormone-Deficiency | TERMINATED | NCT02092077 |
| laboratory biomarker analysis | OTHER | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| decitabine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| omacetaxine mepesuccinate | DRUG | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| cytarabine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | TERMINATED | NCT02029417 |
| MabThera infusions | BIOLOGICAL | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01123070 |
| TL011, anti CD20, for the treatment of rheumatoid arthritis | BIOLOGICAL | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01123070 |
| Laquinimod | DRUG | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00745615 |
| Placebo | DRUG | Phase PHASE2 | Osteoarthritis, Knee | TERMINATED | NCT03949673 |
| 40 mg glatiramer acetate | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT00326625 |
Total products: 76